Ropinirol

A large number of molecules have provided experimental evidence of neuroprotection in in vitro and in vivo models of Parkinson s disease and many of these putative neuroprotective substances are now the objects of clinical trials. Recently, a team of experts has identified potential neuroprotective agents to be tested in pilot studies [4]. Twelve compounds have been considered for clinical trials caffeine, coenzyme Q 10, creatine, estrogen, GPI1485, GM-1 ganglioside, minocycline, nicotine, pramipexole, ropinirol, rasagiline, and selegiline (for individual discussion see [4]). 

Mirapex), and ropinirole (Requip) are newer drugs used in the treatment of Parkinson s disease Drag-induced parkinsonism is treated with the anticholinergics benz-tropine (Cogentin) and trihexyphenidyl (Artane). 

The dopamine receptor agonists, such as pramipexole (Mirapex) and ropinirole (Requip), are used for die treatment of die signs and symptoms of Parkinson s disease... 

The most common adverse reactions seen with pramipexole and ropinirole include nausea, dizziness, postural hypotension, hallucinations, somnolence, vomiting, confusion, visual disturbances, abnormal involuntary movements, and headache... 

The phenotiiiazines may decrease the effectiveness of tiie dopamine receptor agonists. When pramipexole is administered concurrently witii cimetidine, ranitidine, verapamil, and quinidine, there is an increased effect of pramipexole When ropinirole is administered with the estrogens, particularly estradiol, there may be an increased effect of ropinirole... 

Ropinirole 6 mg PO is prescribed. The drug is available in 2-mg tablets. The nurse administers. ... 

C2H3CIO 75-36-5) see Acebutolol Acetiamine Acetylcholine chloride L-Alanine Benfurodil hemisuccinate . Chlorprothixene Flumetasone Ibuprofen lotalamic acid loxitalamic acid Levodopa Methestrol dipropionate Midecamycin acetate Naproxen Nimesulide Paclitaxel Paramethasone Phensuximide Retinol Rocuronium bromide Rofecoxib Ropinirole Tazarotene Thiopropazate Tiracizine Vecuronium bromide... 

QHioO 493-05-0) see Ropinirole 2-isocyanatodiphenyIniethane (C14H11NO 146446-96-0) see Perlapine l-[3-isocyanato-4-(phenyImethoxy)phenyl)ethanone (CifiHijNOj 55057-75-5) see Carbuterol 6 3-isocyanopenicillanic acid benzyl ester (Ci HifjNjOjS 53628-27-6) see Temocillin isoeugenol... 

CH3NO2 75-52-5) see Baclofen Gabapentin Midazolam Pirbuterol Ranitidine Ropinirole Trometaniol l-(2-nitro-4-methoxyphenyl)-2-nitropropcnc C oHi()N203 25803-11-6) see Clometacin 4-(5-nitro-l-methylindol-3-ylmethyl)-3-methoxybenzoic acid... 

C7H7CIO2S 98-59-9) see Benproperine Brinzolamide Carzenide Cefoxitin Diazepam Flurotyl Fosinopril Gusperimus trihydrochloride Idarubicin Idoxuridine Indeloxacine Levocabastine Mazindol Medazepam Mibefradil hydrochloride Nemonapride Pioglitazone Prenalterol Ropinirole Tinidazole Tolterodine p-toluenesulfonamide... 

Opioids, benzodiazepines, barbiturates, corticosteroids, dopamine agonists (e.g., amantadine, bromocriptine, levodopa, pergolide, pramipexole, ropinirole), H2-receptor antagonists, anticholinergics (e.g., diphenhydramine, trihexylphenidyl), P-adrenergic blockers, clonidine, methyldopa, carbamazepine, phenytoin, baclofen, cyclobenzaprine, lithium, antidepressants (e.g., tricyclic antidepressants, selective serotonin reuptake inhibitors), and interleukin-2... 

Ropinirole (Requip ) Activate postsynaptic D2 DA receptors Start with 0.25 mg three times daily increase about weekly by 0.75-1.5 mg daily to a MD dose of 3-8 mg three times daily... 

CH returns to the clinic 3 months later. The physician previously diagnosed him with obstructive sleep apnea and RLS. He received a prescription for CPAP, for OSA and ropinirole 0.5 mg at bedtime for RLS at his last visit. Via phone calls, his ropinirole dose has been increased to 3 mg at bedtime. He has received moderate relief of his RLS symptoms, but on occasion, he still awakens and cannot fall back asleep. His sleepiness and RLS symptoms are improved ESS 13/24. 

Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 2003 87 631-641. 

Ferreira J. J., Galitzky M Thalamas C. et al. (2002). Effect of ropinirole on sleep onset a randomized placebo controlled study in healthy volunteers. Neurology 58(3), 460-2. 

The most important alternatives to levodopa therapy are direct-acting dopamine receptor agonists, such as ropinirole,pramipexole, or pergolide (Fig. 46-5). A number of studies have shown that use of these agents may help to delay the need for use of levodopa/carbidopa. This has... 

Ropinirole is initiated at 0.25 mg three times daily and increased by 0.25 mg three times daily on a weekly basis to a maximum of 24 mg/day. It is metabolized by cytochrome P450 1A2 fluoroquinolones and smoking may alter ropinirole clearance. 

---